
MedIntelDP is an enduring data platform, established to undertake population-based studies examining the use, safety and (cost)effectiveness of prescribed medicines.
The MedIntelDP cohort (N=7,821,610) comprises Medicare-eligible persons (ascertained from the Medicare Consumer Directory) who were aged ≥18 years and resided in NSW at any time from 1 January 2005 until 31 December 2020. The cohort will be updated annually.
The Australian Institute of Health and Welfare (AIHW) and the NSW Centre for Health Record Linkage (CHeReL) undertook the linkage using best practice privacy preserving protocols. The content data comprised Commonwealth and New South Wales routinely collected health data (see list below).
This research program has ethical approval from: (1) AIHW Human Research Ethics Committee (AIHW HREC) (approval number EO2021/1/1233); (2) NSW Population and Health Services Research Ethics Committee (PHSREC) (approval number 2020/ETH02273). Individual research projects conducted under this ethical approval require the submission of an amendment to the PHSREC along with an AIHW s29 form, for each person requiring data access, prior to commencement (approval within 2-4 weeks).
The data are housed in the Secure Unified Research Environment (SURE), managed by the Sax Institute. SURE is a safe setting offering data controls meeting the highest data governance and security requirements. Housing the data in SURE adheres to the Five Safes framework—safe people, projects, settings and outputs. All access and data analyses are via the SURE.
If you wish to access MedIntelDP you will need to work with the MedIntel team to:
For all inquiries, documentation and templates please contact the Data Manager, Medicines Intelligence Research Program, Melisa Litchfield.
The establishment of MedIntelDP was funded by the UNSW Research Infrastructure Scheme and the NHMRC Centre of Research Excellence in Medicines Intelligence.
Pease contact the Data Manager, Medicines Intelligence Research Program, Melisa Litchfield.